Citations

Clear

2303 citation(s) found for "Yu, Edward".

Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study
Ali, Sasha Saadia, Naveen, R, Sen, Parikshit , Day, Jessica , Joshi, Mrudula , Nune, Arvind , Nikiphorou, Elena , Saha, Sreoshy , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Jagtap, Kshitij , Parodis, Ioannis , Kuwana, Masataka , Makol, Ashima , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Halabi, Hussein , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, for the COVAD Study, Kardeş, Sinan , Lini, Daniele , Schreiber, Karen, Vince, Melinda Nagy, Singh, Yogesh Preet , Jain, Avinash , Pandya, Sapan C , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal, Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit , Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Giollo, Alessandro , Alluno, Alessia, Ioannone, Florenzo, Fornaro, Marco, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji, Kaneko, Yuko , Tomaras, Stylianos , Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, François, Meyer, Alain , Limaye, Vidya , Hudson, Marie , Landon‐Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, M Idania, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Ravichandran, Naveen , Schreiber, Karen , Gupta, Latika , Naveen, R , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Chen, Yi-Ming , Makol, Ashima , Agarwal, Vishwesh , Pauling, John D , Wincup, Chris , Barman, Bhupen , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Katchamart, Wanruchada , Shumnalieva, Russka , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Vaidya, Binit , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Distler, Oliver , Saavedra, Miguel A , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Milchert, Marcin , Joshi, Mrudula , Day, Jessica , Velikova, Tsvetelina , Parodis, Ioannis , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Nune, Arvind , Sen, Parikshit , Saha, Sreoshy , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Gracia‐Ramos, Abraham Edgar , Chen, Yi‐Ming , Agarwal, Vishwesh , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Chatterjee, Tulika , Distler, Oliver , Aggarwal, Rohit , Group, for the COVAD Study, Andréoli, Laura , Ranjan, Rajiv , Pilania, Rakesh Kumar , Sharma, Aman , Gupta, Vikas , Kavadichanda, Chengappa G. , Ajmani, Sajal , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Grignaschi, Silvia , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Gonzalez, Raquel Aranega, Yoshida, Akira, Kimura, Naoki, Gono, Takahisa , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Griger, Zoltán , Hmamouchi, Ihsane , Baba, Zineb, Giannini, Margherita , Maurier, F. , Campagne, Julien , Langguth, Daman , Needham, Merrilee , Srivastav, Nilesh , Landon‐Cardinal, Océane , Arbeláez-Cortés, Álvaro , Cajas, Javier, Fonseca, João Eurico , Zimba, Olena , Ima-Edomwonyi, Uyi, Emorinken, Airenakho , So, Ho , Ugarte‐Gil, Manuel F. , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | April 2, 2023 | Volume: 62 | Issue: 9 | Pages: e263-e268

10.1093/rheumatology/kead149 | PMID 37004201 Get It

Racial and Ethnic Disparities in the Use and Outcomes of Transcatheter Mitral Valve Replacement: Analysis From the National Inpatient Sample Database
Ismayl, Mahmoud , Abbasi, Muhannad , Al‐Abcha, Abdullah , El‐Am, Edward , Walters, Ryan W. , Goldsweig, Andrew M. , Alkhouli, Mohamad , Guerrero, Mayra , Anavekar, Nandan S., Abbasi, Muhannad Aboud , Alkhouli, Mohamad , Guerrero, Mayra E , Goldsweig, Andrew M , Al-Abcha, Abdulah , Ismayl, Mahmoud

Mayo Clinic

Journal of the American Heart Association | March 28, 2023 | Volume: 12 | Issue: 7 | Pages: No page available

10.1161/jaha.122.028999 | PMID 36974752 Get It

Background Racial and ethnic disparities in outcomes exist following many cardiac procedures. Transcatheter mitral valve replacement (TMVR) has grown as an alternative to mitral valve surgery for patients at high surgical risk. The outcomes of TMVR by race and ethnicity are unknown. We aimed to evaluate racial and ethnic disparities in the outcomes of TMVR. Methods and Results We analyzed the National Inpatient Sample database from 2016 to 2020 to identify hospitalizations for TMVR. Racial and ethnic disparities in TMVR outcomes were determined using logistic regression models. Between 2016 and 2020, 5005 hospitalizations for TMVR were identified, composed of 3840 (76.7%) White race, 505 (10.1%) Black race, 315 (6.3%) Hispanic ethnicity, and 345 (6.9%) from other races (Asian, Pacific Islander, American Indian or Alaska Native, Other). Compared with other racial and ethnic groups, Black patients were significantly younger and more likely to be women (both P <0.01). There were no significant differences between White, Black, and Hispanic patients in in‐hospital mortality (5.2% versus 5.0% versus <3.5%; P =0.89) and procedural complications, including heart block ( P =0.91), permanent pacemaker ( P =0.49), prosthetic valve dysfunction ( P =0.45), stroke ( P =0.37), acute kidney injury ( P =0.32), major bleeding ( P =0.23), and blood transfusion ( P =0.92), even after adjustment for baseline characteristics. Adjusted vascular complications were higher in Black compared with White patients ( P =0.03). Trend analysis revealed a significant increase in TMVR in all racial and ethnic groups from 2016 to 2020 ( P trend <0.05). Conclusions Between 2016 and 2020, Black and Hispanic patients undergoing TMVR had similar in‐hospital outcomes compared with White patients, except for higher vascular complications in Black patients. Further comparative studies of TMVR in clinically similar White patients and other racial and ethnic groups are warranted to confirm our findings.
Threshold-Responsive Colorimetric Sensing System for the Continuous Monitoring of Gases
Mo, Manni , Fu, Bo , Hota, Piyush , Cay-Durgun, Pinar , Cheng, Edward H., Wiktor, Peter , Tsow, Francis , Thomas, Leslie F., Lind, Mary Laura , Forzani, Erica , Thomas, Leslie, Wang, Ran

Mayo Clinic

Sensors | March 27, 2023 | Volume: 23 | Issue: 7 | Pages: 3496

10.3390/s23073496 | PMID 37050555 Get It

Colorimetric sensors are widely used because of their inherent advantages including accuracy, rapid response, ease-of-use, and low costs; however, they usually lack reusability, which precludes the continuous use of a single sensor. We have developed a threshold-responsive colorimetric system that enables repeated analyte measurements by a single colorimetric sensor. The threshold responsive algorithm automatically adjusts the sensor exposure time to the analyte and measurement frequency according to the sensor response. The system registers the colorimetric sensor signal change rate, prevents the colorimetric sensor from reaching saturation, and allows the sensor to fully regenerate before the next measurement is started. The system also addresses issues common to colorimetric sensors, including the response time and range of detection. We demonstrate the benefits and feasibility of this novel system, using colorimetric sensors for ammonia and carbon dioxide gases for continuous monitoring of up to (at least) 60 detection cycles without signs of analytical performance degradation of the sensors.
Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time
Power, Erica A. , Rechberger, Julian S. , Zhang, Liang , Oh, Ju‐Hee , Anderson, Jacob B. , Ge, Jizhi, Hinchcliffe, Edward H. , Elmquist, William F. , Nesvick, Cody L. , Power, Erica A , Rechberger, Julian S , Anderson, Jacob B , Daniels, David J.

Mayo Clinic

Neuro-Oncology Advances | March 27, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdad033 | PMID 37128506 Get It

Abstract Background H3K27-altered diffuse midline glioma (DMG) is the deadliest pediatric brain tumor; despite intensive research efforts, every clinical trial to date has failed. Is this because we are choosing the wrong drugs? Or are drug delivery and other pharmacokinetic variables at play? We hypothesize that the answer is likely a combination, where optimization may result in a much needed novel therapeutic approach. Methods We used in vitro drug screening, patient samples, and shRNA knockdown models to identify an upregulated target in DMG. A single small molecule protein kinase inhibitor with translational potential was selected for systemic and direct, loco-regional delivery to patient-derived xenografts (PDX) and genetically engineered mouse models (GEMM). Pharmacokinetic studies were conducted in non-tumor bearing rats. Results Aurora kinase (AK) inhibitors demonstrated strong antitumor effects in DMG drug screens. Additional in vitro studies corroborated the importance of AK to DMG survival. Systemic delivery of alisertib showed promise in subcutaneous PDX but not intracranial GEMM and PDX models. Repeated loco-regional drug administration into the tumor through convection-enhanced delivery (CED) was equally inefficacious, and pharmacokinetic studies revealed rapid clearance of alisertib from the brain. In an effort to increase the drug to tumor residence time, continuous CED over 7 days improved drug retention in the rodent brainstem and significantly extended survival in both orthotopic PDXs and GEMMs. Conclusions These studies provide evidence for increasing drug-tumor residence time of promising targeted therapies via extended CED as a valuable treatment strategy for DMG.
Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period—a cross-sequential study based on COVAD surveys
Jagtap, Kshitij , Naveen, R, Day, Jessica , Sen, Parikshit , Vaidya, Binit , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Agarwal, Vishwesh , Saha, Sreoshy , Ziadé, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Kuwana, Masataka , Makol, Ashima , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Halabi, Hussein , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Group, COVAD Study, Kardeş, Sinan , Schreiber, Karen, Vince, Melinda Nagy, Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit , Atzeni, Fabiola , Bocci, Elena Bartoloni, Sebastiani, Marco, Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Grignaschi, Silvia, Alluno, Alessia, Ioannone, Florenzo, Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos , Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, François, Meyer, Alain , Limaye, Vidya , Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Argueta, Sandra, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, Miguel , Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Ravichandran, Naveen , Gupta, Latika , Naveen, R , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Joshi, Mrudula , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Makol, Ashima , Pauling, John D , Wincup, Chris , Barman, Bhupen , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Shumnalieva, Russka , Chen, Yi-Ming , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Saavedra, Miguel A , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vishwesh , Day, Jessica , Tan, Ai Lyn , Nune, Arvind , Sen, Parikshit , Saha, Sreoshy , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Shinjo, Samuel Katsuyuki , Joshi, Mrudula , Gracia‐Ramos, Abraham Edgar , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Chen, Yi‐Ming , Chatterjee, Tulika , Distler, Oliver , Group, COVAD Study, Griger, Zoltán , Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco, Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Venerito, Vincenzo , Giollo, Alessandro , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Loarce‐Martos, Jesus , Gonzalez, Raquel Aranega, Yoshida, Akira , Kimura, Naoki, Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Baba, Zineb, Giannini, Margherita , Maurier, F. , Campagne, Julien , Langguth, Daman , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Emorinken, Airenakho , Olaosebikan, Hakeem , So, Ho , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Salinas, Rodrigo Nicolás Garcia , Aggarwal, Rohit

Mayo Clinic

Rheumatology | March 24, 2023 | Volume: 62 | Issue: 12 | Pages: 3838-3848

10.1093/rheumatology/kead144 | PMID 36961331 Get It

Abstract Objective Flares of autoimmune rheumatic diseases (AIRDs) following COVID-19 vaccination are a particular concern in vaccine-hesitant individuals. Therefore, we investigated the incidence, predictors and patterns of flares following vaccination in individuals living with AIRDs, using global COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveys. Methods The COVAD surveys were used to extract data on flare demographics, comorbidities, COVID-19 history, and vaccination details for patients with AIRDs. Flares following vaccination were identified as patient-reported (a), increased immunosuppression (b), clinical exacerbations (c) and worsening of PROMIS scores (d). We studied flare characteristics and used regression models to differentiate flares among various AIRDs. Results Of 15 165 total responses, the incidence of flares in 3453 patients with AIRDs was 11.3%, 14.8%, 9.5% and 26.7% by definitions a–d, respectively. There was moderate agreement between patient-reported and immunosuppression-defined flares (K = 0.403, P = 0.022). Arthritis (61.6%) and fatigue (58.8%) were the most commonly reported symptoms. Self-reported flares were associated with higher comorbidities (P = 0.013), mental health disorders (MHDs) (P &lt; 0.001) and autoimmune disease multimorbidity (AIDm) (P &lt; 0.001). In regression analysis, the presence of AIDm [odds ratio (OR) = 1.4; 95% CI: 1.1, 1.7; P = 0.003), or a MHD (OR = 1.7; 95% CI: 1.1, 2.6; P = 0.007), or being a Moderna vaccine recipient (OR = 1.5; 95% CI: 1.09, 2.2; P = 0.014) were predictors of flares. Use of MMF (OR = 0.5; 95% CI: 0.3, 0.8; P = 0.009) and glucocorticoids (OR = 0.6; 95% CI: 0.5, 0.8; P = 0.003) were protective. A higher frequency of patients with AIRDs reported overall active disease post-vaccination compared with before vaccination (OR = 1.3; 95% CI: 1.1, 1.5; P &lt; 0.001). Conclusion Flares occur in nearly 1 in 10 individuals with AIRDs after COVID vaccination; people with comorbidities (especially AIDm), MHDs and those receiving the Moderna vaccine are particularly vulnerable. Future avenues include exploring flare profiles and optimizing vaccine strategies for this group.
Structure-based design and characterization of Parkin-activating mutations
Stevens, Michael , Croteau, Nathalie , Eldeeb, Mohamed A. , Zeng, Zhi Wei , Toth, Rachel , Durcan, Thomas M. , Springer, Wolfdieter , Muqit, Miratul M. K. , Trempe, Jean‐François , Toth, Rachel , Springer, Wolfdieter , Fon, Edward A , Muqit, Miratul Mk , Trempe, Jean-François , Antico, Odetta

Mayo Clinic

Life Science Alliance | March 20, 2023 | Volume: 6 | Issue: 6 | Pages: e202201419

10.26508/lsa.202201419 | PMID 36941054 Get It

Autosomal recessive mutations in the Parkin gene cause Parkinson’s disease. Parkin encodes an ubiquitin E3 ligase that functions together with the kinase PINK1 in a mitochondrial quality control pathway. Parkin exists in an inactive conformation mediated by autoinhibitory domain interfaces. Thus, Parkin has become a target for the development of therapeutics that activate its ligase activity. Yet, the extent to which different regions of Parkin can be targeted for activation remained unknown. Here, we have used a rational structure-based approach to design new activating mutations in both human and rat Parkin across interdomain interfaces. Out of 31 mutations tested, we identified 11 activating mutations that all cluster near the RING0:RING2 or REP:RING1 interfaces. The activity of these mutants correlates with reduced thermal stability. Furthermore, three mutations V393D, A401D, and W403A rescue a Parkin S65A mutant, defective in mitophagy, in cell-based studies. Overall our data extend previous analysis of Parkin activation mutants and suggests that small molecules that would mimic RING0:RING2 or REP:RING1 destabilisation offer therapeutic potential for Parkinson’s disease patients harbouring select Parkin mutations.
Guidelines for High-Quality Three-Dimensional Models Using Photogrammetry: A Technical Note on the Future of Neuroanatomy Education
Oliveira, André de Sá Braga , Leonel, Luciano, LaHood, Edward R., Hallak, Hana , Link, Michael J. , Peris‐Celda, Maria , Morris, Jonathan M. , Pinheiro‐Neto, Carlos

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1762327 Get It

Foundations and guidelines for high‐quality three‐dimensional models using photogrammetry: A technical note on the future of neuroanatomy education
Oliveira, André de Sá Braga , Leonel, Luciano, LaHood, Edward R., Hallak, Hana , Link, Michael J. , Maleszewski, Joseph J. , Pinheiro‐Neto, Carlos , Morris, Jonathan M. , Peris‐Celda, Maria , Leonel, Luciano César Pereira Campos , Pinheiro-Neto, Carlos D , Morris, Jonathan

Mayo Clinic

Anatomical Sciences Education | March 19, 2023 | Volume: 16 | Issue: 5 | Pages: 870-883

10.1002/ase.2274 | PMID 36934316 Get It

Abstract Hands‐on dissections using cadaveric tissues for neuroanatomical education are not easily available in many educational institutions due to financial, safety, and ethical factors. Supplementary pedagogical tools, for instance, 3D models of anatomical specimens acquired with photogrammetry are an efficient alternative to democratize the 3D anatomical data. The aim of this study was to describe a technical guideline for acquiring realistic 3D anatomic models with photogrammetry and to improve the teaching and learning process in neuroanatomy. Seven specimens with different sizes, cadaveric tissues, and textures were used to demonstrate the step‐by‐step instructions for specimen preparation, photogrammetry setup, post‐processing, and display of the 3D model. The photogrammetry scanning consists of three cameras arranged vertically facing the specimen to be scanned. In order to optimize the scanning process and the acquisition of optimal images, high‐quality 3D models require complex and challenging adjustments in the positioning of the specimens within the scanner, as well as adjustments of the turntable, custom specimen holders, cameras, lighting, computer hardware, and its software. MeshLab® software was used for editing the 3D model before exporting it to MedReality® (Thyng, Chicago, IL) and SketchFab® (Epic, Cary, NC) platforms. Both allow manipulation of the models using various angles and magnifications and are easily accessed using mobile, immersive, and personal computer devices free of charge for viewers. Photogrammetry scans offer a 360° view of the 3D models ubiquitously accessible on any device independent of operating system and should be considered as a tool to optimize and democratize the teaching of neuroanatomy.
Experience and opinions relating to pregnancy in patients with chronic intestinal failure: an international survey
Bond, Ashley , Allan, Philip , Conley, Thomas , Farrer, K., Cuerda, Cristina , Joly, Francisca , Lamprecht, Georg , Szczepanek, Kinga , Gossum, A. Van , Wanten, Geert , Lal, Simon , Conley, Thomas Edward , Mundi, Manpreet, Mackillop, Lucy H. , Bozzetti, Federico , Jeppesen, Palle Bekker , Mundi, Manpreet S. , Pironi, Loris

Mayo Clinic

Frontline Gastroenterology | March 19, 2023 | Volume: 14 | Issue: 5 | Pages: 377-383

10.1136/flgastro-2023-102384 | PMID 37581192 Get It

Introduction Pregnancy in patients with chronic intestinal failure (CIF) is a relatively rare occurrence but is an important contemporary topic given both the increasing use of home parenteral nutrition (HPN) and the demographics of patients with CIF. Method An opinion-based survey was produced in a multidisciplinary manner, which was then distributed internationally, via the European Society for Clinical Nutrition and Metabolism network, using a web-based survey tool for healthcare professionals with a specialist interest in the management of CIF. Results Seventy specialists from 11 countries completed the survey. Fifty-four per cent of the respondents reported some experience of managing pregnancy in patients with CIF. However, 60% stated that they did not feel that it was their role to discuss the topic of pregnancy with their patients, with fewer than 10% stating that they routinely did so. Respondents felt that an individualised approach was required when considering alterations to parenteral support prior to conception, during pregnancy and in the postnatal period. Most respondents also felt there was no increased risk of catheter-related blood stream infections, while catheter-related thrombosis was deemed to be the most significant HPN-related complication for pregnant women. Conclusion This study reports a variable experience, knowledge and confidence of healthcare professionals when considering pregnancy in patients with CIF. The risk of HPN-related complication was felt to be greater during pregnancy, with an individualised approach being the preferred route for most aspects of care. The findings support the need for an international registry and subsequent consensus guidelines for the management of pregnancy in CIF.
Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress.
Inman, Brant A. , Kates, Max R., Uchio, Edward , Redorta, Joan Palou, Catto, James W.F. , Kulkarni, Girish S. , Tyson, Mark D. , Haas, Gabriel P., Yu, Yao, Birrenkott, Matthew, Inman, Brant A , Kamat, Ashish M. , Steinberg, Gary D. , Porten, Sima P. , Rouprêt, Morgan , Powles, Thomas , Lotan, Yair

Mayo Clinic

Journal of Clinical Oncology | March 14, 2023 | Volume: 41 | Issue: 6_suppl | Pages: TPS582-TPS582

10.1200/jco.2023.41.6_suppl.tps582 Get It

TPS582 Background: The majority of patients with bladder cancer present with non-muscle invasive disease (Chang 2016; Woldu 2017; Kates 2020; Li 2020). The standard of care for treatment of high risk NMIBC involves transurethral resection of the bladder tumor (TURBT) followed by intravesical Bacillus Calmette-Guerin (BCG) or chemotherapy. Although the response rate to BCG therapy is high, many patients recur within 1–5 years (Matulay JU 2021). For patients who have BCG unresponsive disease after adequate course of BCG, there are limited options. While radical cystectomy (RC) is still considered the standard of care, most patients are reluctant to undergo RC and their options are limited to intravesical chemotherapy or pembrolizumab. Enfortumab vedotin (EV) is an antibody-drug conjugate directed to Nectin-4, which is highly expressed in bladder tumors. In EV-301, a phase 3 study, EV showed an OS benefit vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who had previously received platinum-based therapy and a PD-1 or PD-L1 inhibitor (Powles NEJM 2021). Based on its demonstrated benefit in la/mUC, EV is currently being evaluated in earlier UC settings. The purpose of this study is to investigate the intravesical administration of EV for patients with NMIBC. Methods: EV-104 (NCT05014139) is a phase 1, open-label, multicenter, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, PK, and antitumor activity of intravesical EV in adults with high-risk BCG-unresponsive NMIBC (carcinoma in situ with or without papillary disease) who are ineligible for or refuse RC. The dose escalation part of the trial aims to identify the maximum tolerated dose (MTD) and/or recommended dose of intravesical EV. The dose expansion part will evaluate patients at the MTD or recommended dose and further characterize safety and antitumor activity of intravesical EV. The study treatment regimen will include an induction phase, where patients will receive intravesical EV weekly for 6 weeks followed by monthly maintenance for a total of 9 additional EV doses. Patients will be assessed for response every 3 months by cystoscopy and urine cytology, while on study. Safety and antitumor activity endpoints will be summarized using descriptive statistics. The study is currently enrolling in the US with additional sites planned in Canada and the EU. Clinical trial information: NCT05014139 .